Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Chengjian Mao"'
Publikováno v:
Translational Oncology, Vol 10, Iss 5, Pp 818-827 (2017)
The oncofetal mRNA-binding protein, IMP1 or insulin-like growth factor-2 mRNA-binding protein 2 (IGF2BP1), binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, leading to increased expression of the proteins encoded by its target mRNAs
Externí odkaz:
https://doaj.org/article/be537566efeb4bbeb2163abc0c910b5f
Autor:
Eylem Kulkoyluoglu Cotul, Qianying Zuo, Ashlie Santaliz-Casiano, Ozan Berk Imir, Ayca Nazli Mogol, Elif Tunc, Kevin Duong, Jenna Kathryn Lee, Rithva Ramesh, Elijah Odukoya, Mrinali P. Kesavadas, Monika Ziogaite, Brandi Patrice Smith, Chengjian Mao, David J. Shapiro, Ben Ho Park, Benita S. Katzenellenbogen, Drew Daly, Evelyn Aranda, John D. O’Neill, Christopher Walker, Yosef Landesman, Zeynep Madak-Erdogan
Publikováno v:
Cancers, Vol 12, Iss 9, p 2397 (2020)
The majority of breast cancer specific deaths in women with estrogen receptor positive (ER+) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or ma
Externí odkaz:
https://doaj.org/article/87243b4591a14484aca866d16781cc46
Autor:
Benita S. Katzenellenbogen, John A. Katzenellenbogen, Kendall W. Nettles, David J. Shapiro, Chengjian Mao, Steffi Oesterreich, Ben Ho Park, David Chu, Sung Hoon Kim, Abhishek Sharma, Jian Min, Yvonne Ziegler, Valeria Sanabria Guillen, Mary J. Laws, Yuechao Zhao
Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1b3bdda00200079ea4abf2412993461
https://doi.org/10.1158/0008-5472.c.6509090.v1
https://doi.org/10.1158/0008-5472.c.6509090.v1
Autor:
Benita S. Katzenellenbogen, John A. Katzenellenbogen, Kendall W. Nettles, David J. Shapiro, Chengjian Mao, Steffi Oesterreich, Ben Ho Park, David Chu, Sung Hoon Kim, Abhishek Sharma, Jian Min, Yvonne Ziegler, Valeria Sanabria Guillen, Mary J. Laws, Yuechao Zhao
Figure S1 shows the dose-dependent inhibition of proliferation of T47D cells with wild type or mutant ERα by antiestrogen compounds. Figure S2 shows that the three antiestrogen compounds (K-07, K-09, K-62) and trans-hydroxytamoxifen suppress binding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e82e321627d738bcffc7bc3f2c6548
https://doi.org/10.1158/0008-5472.22414856.v1
https://doi.org/10.1158/0008-5472.22414856.v1
Autor:
Theodore M. Tarasow, Matthew W. Boudreau, Chengjian Mao, Geoffrey L. Greene, Bingtao Tang, Darjan Duraki, Spyro Mousses, Timothy M. Fan, Jeff Kiefer, Madeline A. Henn, Paul J. Hergenrother, Ben Ho Park, Elizabeth M. Bruckheimer, Sean W. Fanning, Ramon Moreno, Lawrence Wang, Erik R. Nelson, David J. Shapiro, Edward J. Roy, Ji Eun Kim
Publikováno v:
Sci Transl Med
Metastatic estrogen receptor α (ERα)-positive breast cancer is presently incurable. Seeking to target these drug-resistant cancers, we report the discovery of a compound, called ErSO, that activates the anticipatory unfolded protein response (a-UPR
Autor:
Darjan Duraki, Paul J. Hergenrother, Matthew W. Boudreau, Chengjian Mao, Ben Ho Park, Lawrence Wang, Bingtao Tang, Timothy M. Fan, Erik R. Nelson, Edward J. Roy, David J. Shapiro, Liqian Ma
Publikováno v:
Journal of the Endocrine Society
Metastatic estrogen receptor α (ERα) positive breast cancer is presently incurable and most patients die within 7 years. From a medicinal chemistry program, we identified a novel small molecule that acts through ERα to kill breast cancer cells and
Autor:
Evelyn Aranda, Brandi Patrice Smith, Rithva Ramesh, Ayca Nazli Mogol, David J. Shapiro, Ozan Berk Imir, Zeynep Madak-Erdogan, Jenna Kathryn Lee, Qianying Zuo, Mrinali P. Kesavadas, Chengjian Mao, Drew Daly, John D. O’Neill, Yosef Landesman, Ashlie Santaliz-Casiano, Elif Tunc, Monika Ziogaite, Christopher J. Walker, Eylem Kulkoyluoglu Cotul, Ben Ho Park, Kevin Duong, Benita S. Katzenellenbogen, Elijah Odukoya
Publikováno v:
Cancers
Volume 12
Issue 9
Cancers, Vol 12, Iss 2397, p 2397 (2020)
Volume 12
Issue 9
Cancers, Vol 12, Iss 2397, p 2397 (2020)
The majority of breast cancer specific deaths in women with estrogen receptor positive (ER+) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or ma
Autor:
Lawrence Wang, Liqian Ma, Edward J. Roy, Bingtao Tang, Matthew W. Boudreau, Chengjian Mao, David J. Shapiro, Timothy M. Fan, Paul J. Hergenrother, Darjan Duraki, Erik R. Nelson, Ben Ho Park
Publikováno v:
Journal of the Endocrine Society
Metastatic estrogen receptor α (ERα) positive breast cancer is presently incurable and most patients die within 7 years. From a medicinal chemistry program, we identified a novel small molecule that acts through ERα to kill breast cancer cells and
Autor:
Sung Hoon Kim, Jian Min, David J. Shapiro, Kendall W. Nettles, Yvonne S. Ziegler, Valeria Sanabria Guillen, David Chu, Mary J. Laws, Benita S. Katzenellenbogen, Abhishek Sharma, Chengjian Mao, Yuechao Zhao, John A. Katzenellenbogen, Ben Ho Park, Steffi Oesterreich
Publikováno v:
Cancer Research. 77:5602-5613
Many estrogen receptor α (ERα)–positive breast cancers develop resistance to endocrine therapy via mutation of ERs whose constitutive activation is associated with shorter patient survival. Because there is now a clinical need for new antiestroge
Autor:
Stephen B. Gruber, Neal Andruska, Chengjian Mao, Leon Raskin, Douglass R. Fullen, Lily Mahapatra, David J. Shapiro, Timothy M. Johnson
Publikováno v:
Melanoma Res
The oncofetal mRNA binding protein, IMP1 or insulin-like growth factor-2 mRNA-binding protein 1 [IGF2BP1], promotes the overexpression of several oncogenic proteins by binding to and stabilizing their mRNAs. IMP1 is frequently overexpressed in melano